Amedisys Inc Stock News

BATON ROUGE, La., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care services, today announced that Chris

BATON ROUGE, La., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care services, today announced that Chris Gerard, President and Chief Operating Officer and Scott Ginn, Executive Vice President and Chief Financial Officer, will present at the Raymond James & Associates’ 43 rd Annual Institutional Investors Conference on Tuesday, March 8, at 11:35 a.m. EST.

BATON ROUGE, La., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care services, today announced that Chris G

Analysts have provided the following ratings for Amedisys (NASDAQ:AMED) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 4 1 0 0 Last 3

Analysts have provided the following ratings for Amedisys (NASDAQ: AMED ) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 4 1 0 0 Last 30D 0 3 0 0 0 1M Ago 1 0 1 0 0 2M Ago 0 0 0 0 0 3M Ago 0 1 0 0 0 In the last 3 months, 6 analysts have offered 12-month price targets for Amedisys. The company has an average price target of $186.67 with a high of $213.00 and a low of $147.00. Below is a summary of how these 6 analysts rated Amedisys over the past 3 months. The greater the number of bullish ratings, the more … Full story available on Benzinga.com

Amedisys <> has stretched its post-earnings gains further on Friday after BMO Capital Markets upgraded the healthcare services firm on the strength of its 2022 outlook and…

Upgrades According to 86 Research, the prior rating for NetEase Inc (NASDAQ:NTES) was changed from Hold to Buy. For the fourth quarter, NetEase had an EPS of $1.56, compared to year-ago quarter EPS o

Amedisys, Inc. (AMED) CEO Paul Kusserow on Q4 2021 Results - Earnings Call Transcript

The following discussion and analysis provides information we believe is relevant to an assessment and understanding of our results of operations and financial condition for 2021, 2020 and 2019. For a discussion of a comparison of the years ended December 31, 2020 and December 31, 2019, please refer to "Management''s Discussion and Analysis of Financial… The post AMEDISYS INC – 10-K – MANAGEMENT''S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS appeared first on InsuranceNewsNet .

Amedisys (AMED) delivered earnings and revenue surprises of 0.86% and 0.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

BATON ROUGE, La. (AP) _ Amedisys Inc. (AMED) on Wednesday reported fourth-quarter earnings of $34 million. On a per-share basis, the Baton Rouge, Louisiana-based company said it had net income of $1.04. Earnings, adjusted for non-recurring costs, came to $1.18 per share. The results surpassed Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $1.17 per share. The home health care and hospice services provider posted revenue of $559.3 million in the period, also surpassing Street forecasts. Seven analysts surveyed by Zacks expected $555.3 million. For the year, the company reported profit of $209.1 million, or $6.34 per share. Revenue was reported as $2.21 billion. Amedisys expects full-year earnings in the range of $5.23 to $5.45 per share, with revenue in the range of $2.33 billion to $2.37 billion. Amedisys shares have decreased 17% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $134.90, a decline of 52% in the last 12 months. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research.

BATON ROUGE, La., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2021.

BATON ROUGE, La., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2021.